Lipids & metabolic liver disease
Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study
Main finding · Incident end-stage renal diseaseResult — go to the resultHazard ratio 0.763 95% CI 0.710–0.821Authors' conclusion
Fenofibrate use in patients taking statins with either hypertension, proteinuria, or decreased estimated glomerular filtration rate is associated with a low risk of incident end-stage renal disease. To confirm the renoprotective effect of fenofibrate in chronic kidney disease, a randomized controlled trial is warranted.
Study context
- Population
- Adults using statins, Korea National Health Information Database, 2010–2017matched cohort
- Participants
- 413,715 vs 413,715
- Exposure
- Fenofibrate users vs fenofibrate non-users among statin users
- Fenofibrate usersn = 413,715
- Fenofibrate non-usersn = 413,715reference
- Outcome
- Incident end-stage renal disease
- Follow-up
- median 3.96-year follow-up
Methodological detailsnationwide, 1:1 age, sex and triglyceride matching
- Nationwide
- 1:1 age, sex and triglyceride matching
Main finding
As reported in the abstract
Hazard ratio
0.763
95% CI 0.710–0.821
By group
Fenofibrate users
0.885 per 1000 person years
Fenofibrate non-users
0.960 per 1000 person years
Fenofibrate usersvs Fenofibrate non-users
HR 0.763 (95% CI 0.710–0.821)
Observational data: associations, not effects.
Further findings
End-stage renal disease by subgroup
- Association significant in patients with hypertension, proteinuria and eGFR <60 mL/min/1.732
Original publication
Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study. Diabetes Obes Metab. Published 29 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →